|Page (1) of 1 - 02/08/18||email article||print page|
(February 08, 2018)
BEIJING, CHINA - February 8, 2018 - Shandong Sinobioway Biomedicine Co., Ltd. (SZSE: 002581) (“Shandong Sinobioway”) announced today that it has learned that at the close of the 2017 Annual Meeting of Shareholders of Sinovac Biotech Ltd. (NasdaqGS: SVA) (“Sinovac Biotech” or the “Company”) held yesterday morning, the Company’s inspector of elections, Helen Yang, announced the results of the matters voted at the meeting. Four nominees, Guowei Wang, Hoi Fung Qiu, Jianzeng Cao, and Pengfei Li, and one of the incumbent directors, Yuk Lam Lo, received 55.19 percent of all votes present and voting at the meeting. Four members of the incumbent board, Weidong Yin, Kenneth Lee, Meng Mei and Simon Anderson, were defeated by the same margin.
Shandong Sinobioway,on behalf of Sinobioway Consortium, issued the following statement:
“Sinobioway Consortium applauds the Company’s shareholders for electing Guowei Wang, Hoi Fung Qiu, Jianzeng Cao, Pengfei Li, and Yuk Lam Lo. This is a milestone event in the history of shareholder democracy and corporate governance. We look forward to their prompt installation and wish both them and the Company great success under their stewardship.”
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to over 10 countries in Asia and South America.Media Contact
Company Name: Shandong Sinobioway Biomedicine Co., Ltd.
Contact Person: Yizhe Wang
Email: [email protected]
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter